Helping detect aggressive prostate cancer, easier, faster, better
Prostate cancer is the most common cancer affecting men, about 1 in 7 are diagnosed annually. Each year in Canada, thousands of men undergo invasive biopsies, essentially 12 needles through the prostate, to detect cancer and/or monitor its progression. Now, there is a new tool to help better identifying which men actually need a biopsy. The tool a "simple blood test” developed by UAlberta researchers. The test uses a liquid biopsy platform, nanotechnology and machine learning to identify aggressive prostate cancer. For patients, the test is easy, requiring just two drops of blood. Clinical data found the test, called Clarity DX, correctly identifies men with aggressive prostate cancer 40% more accurately that the commonly used PSA test.
Nanostics Inc., a UAlberta spin-off, was created to move the new technology out of the lab and into doctors hands. In addition to improving men’s diagnostic experience and quality of life, Clarity DX could eventually eliminate up to 600,000 unnecessary biopsies, 24,000 hospitalizations and up to 50% of unnecessary treatment in North America alone. There is also technology cost savings—Clarity DX is expected to cost several hundred dollars vs. around $2,000 for a biopsy